Biophore India Pharmaceuticals, Hyderabad, has applied to the Drugs Controller General of India (DCGI) for permission to use the drug to treat Covid patients from mild to severe symptoms. Biophore CEO Jagadish Babu Rangishetti said he had applied for an emergency permit for the inhaled ‘Aviptadil’.
Biophore developed Aviptadil, including Active Pharmaceutical Ingredient (API) for the treatment of Covid. The company will commercialize the drug as soon as it is approved. Aviptadil is a synthetic form of Human Vasoactive intestinal peptide (VIP). Jagadish Babu said that if DCGI approval is obtained, it can be launched in the market immediately.